openPR Logo
Press release

Pompe Disease Market : Size, Status and Forecast 2016 - 2024

07-18-2017 08:17 PM CET | Health & Medicine

Press release from: Transparency Market Research

Pompe Disease Market : Size, Status and Forecast 2016 - 2024

Pompe disease is a rare, progressive, autosomal recessively inherited metabolic disorder, and is often a fatal muscular disease that affects one of the lysosomal enzymes. Pompe disease can also be called as a glycogen storage disease or acid alpha-glycosidase deficiency or GAA deficiency. It mainly occurs due to accumulation of glycogen in some tissues and organs, particularly muscles, leading to abnormal functioning. The inability of breaking the lysosomal glycogen lies in the mutation of a gene responsible for production of the enzyme acid alpha-glycosidase. This enzyme breaks glycogen into simpler form i.e. glucose but a mutation in the GAA gene prevents this activity. The stoppage of glycogen breakdown causes massive cellular dysfunction, with the marked involvement of the cardiac, smooth, and skeletal muscle. 

View Report @ http://www.transparencymarketresearch.com/pompe-disease-market.html

Pompes disease is categorized on the basis of disease severity, disease progression and age, such as infantile-onset, non-classic infantile-onset and late onset. Within few months of birth, the infantile onset of Pompes disease starts showing its symptoms such as enlarged liver(hepatomegaly),muscle weakness(myopathy), heart defect, and poor muscle tone (hypotony).The infants affected with this disease face challenges of weight gain as well as hampered growth and breathing problems. The affected infant may have large protruding tongue. If untreated, the infant may die of heart failure in the first year of life itself. Non-Classic infantile-onset is usually seen at the age of 1 year. The disease symptoms include poor motor skills and a delayed muscle progress .They may show signs of hearing impairment and abnormally large heart. The muscle weakness may seriously lead to breathing problems. The Late-onset marks its symptoms by later stages of childhood, adolescent age or in adulthood. This form of late onset is a bit milder than the previous ones and doesn’t involve heart. The muscle weakness is generally observed in the legs, trunk and breathing muscles. The progress of the disorder in the muscles controlling breathing will ultimately lead to the respiratory failure.

Pompes disease can occur in various age groups and population across the world. The occurrence of the disease is 1 in 40,000 births in the U.S. In many cases, the people suffering from Pompes Disease in late onset of the disease remain undiagnosed. The symptoms of Pompes Disease are observed due to the complete or partial deficiency of the GAA enzyme. Diagnosis of Pompe disease can be performed by GAA activity assay. Following are the tests for the detection of Pompe disease:

Sequencing of the GAA gene
GAA activity assay in blood, cultured amniocytes, chorionic villi and cultured skin fibroblasts.
The marker, urinary hexose tetrasaccharide can be used to keep a track of patients suffering from Pompe disease
Cross Reactive Immunological Material (CRIM) analysis
Pompe disease can be treated by symptomatic, supportive and disease-specific ways. As the disease involves impairment of cardiac, respiratory and muscular systems, the treatment necessitates requirement of specialists with expertise in all these disorders. Cardiologists, dieticians, pediatricians, orthopedists may need to co-ordinate and design a well collaborated treatment plan for the patient. The US Food and Drug Administration has approved an enzyme replacement therapy- Myozyme® for the infantile onset of Pompe disease suffering patients of less than 8 years old. Whereas Lumizyme® is used for patients older than 8 years of age. The genetically engineered human GAA enzyme is administered intravenously every two weeks.

Get accurate market forecast and analysis on the Pompe Disease Market. Request a sample to stay abreast on the key trends impacting this market.

http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14102

Increasing developments in the gene therapy and enzyme replacement therapies are driving factors for the growth of Pompe disease market. However, affordability of the expensive therapy treatments may pose a potential threat to these markets in developing markets. Major market players in the field of Pompe Disease therapeutics are Genzyme, BioMarin Pharmaceutical, and Amicus Therapeutics.There are some key vendors like Audentes Therapeutics, EpiVax, Oxyrane, Sangamo BioSciences, and Valerion Therapeutics.

The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape. 

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pompe Disease Market : Size, Status and Forecast 2016 - 2024 here

News-ID: 630489 • Views:

More Releases from Transparency Market Research

Handheld Marijuana Vaporizer Market Key Drivers, Market Research, and Insights for the USD 15.9 Bn Market 2022-2031
Handheld Marijuana Vaporizer Market Key Drivers, Market Research, and Insights f …
The global handheld marijuana vaporizer market has witnessed remarkable growth in recent years, attributed to the increasing acceptance of medicinal marijuana and the demand for convenient and discreet consumption methods. Valued at US$ 5 billion in 2021, the market is projected to surge at a CAGR of 13.4% to reach US$ 15.9 billion by 2031. This article delves into the factors driving this growth, the evolving market landscape, and the
Disinfectant Wipes Market Forecast 2020-2030 - Market Size, Drivers, Trends, And Competitors
Disinfectant Wipes Market Forecast 2020-2030 - Market Size, Drivers, Trends, And …
The COVID-19 pandemic has precipitated a remarkable surge in the demand for disinfectant products, with a notable emphasis on disinfectant wipes as an essential tool in maintaining hygiene and preventing the spread of pathogens. This research report delves into the multifaceted landscape of the disinfectant wipes market, elucidating key trends, drivers, and innovations shaping the industry. 𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=70359 Key Players and Market Developments Key players
Tissue Banking Market is Expected to Reach US$ 2,903.3 Million to 2026| TMR Study
Tissue Banking Market is Expected to Reach US$ 2,903.3 Million to 2026| TMR Stud …
The global 𝐭𝐢𝐬𝐬𝐮𝐞 𝐛𝐚𝐧𝐤𝐢𝐧𝐠 𝐦𝐚𝐫𝐤𝐞𝐭 reached a value of US$ 1,056.4 million in 2017 and is projected to nearly triple to US$ 2,903.3 million by 2026, with a robust Compound Annual Growth Rate (CAGR) of approximately 12.0% from 2018 to 2026. Factors such as increasing awareness about tissue donation, technological advancements, and a growing target patient population are anticipated to propel market growth during this period. Moreover, the market is expected
Vascular Closure Devices Market to reach US$ 1 Billion by 2027: TMR Study
Vascular Closure Devices Market to reach US$ 1 Billion by 2027: TMR Study
This report by Transparency Market Research, Inc. assesses the present state and future growth potential of the global 𝐯𝐚𝐬𝐜𝐮𝐥𝐚𝐫 𝐜𝐥𝐨𝐬𝐮𝐫𝐞 𝐝𝐞𝐯𝐢𝐜𝐞𝐬 𝐦𝐚𝐫𝐤𝐞𝐭. It features a comprehensive executive summary, offering insights into various segments of the market. Additionally, the report provides detailed analysis and data on product, access type, application, end user, and regional segments within the global market. Vascular closure devices is estimated to reach a value of ~US$ 1 Bn

All 5 Releases


More Releases for Pompe

Pompe Disease Therapeutic Market - Increasing prevalence of pompe disease in man …
Pompe Disease Therapeutic Market report is a exploration database spread across colorful runners with multiple tables and numbers in it. The exploration covers a precious source of perceptive information for business strategists. Pompe Disease Therapeutic Industry provides the overview with growth analysis and literal & futuristic cost, profit, demand and force data (as applicable). The exploration judges give an elegant description of the value chain and its distributor analysis. This comprehensive
Pompe Disease Drug Market Epidemiology 2030| Delveinsight
DelveInsight's Pompe Disease Market Insights, Epidemiology, and Market Forecast 2030 report delivers an in-depth understanding of the Pompe Disease, historical and forecasted epidemiology as well as the Pompe Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Pompe Disease market report provides current treatment practices, emerging drugs, Pompe Disease market share of the individual therapies, current and forecasted Pompe Disease market Size
Pompe Disease Therapeutic Market - Attractive Growth Opportunities 2017 - 2025
Manufacturers are focusing on finding new solutions by expanding their pipeline to cater the demand for pompe disease therapeutics market. For instance, in September, 2017, Avrobio Inc. expanded their products pipeline with gene therapy to treat pompe disease by utilizing a proprietary lysosomal targeting sequence to deliver high levels of enzyme to lysosomes. Furthermore, in October 2017, Amicus Therapeutics received orphan drug designation to ATB200/AT2221 from the U.S. FDA for
Pompe Disease Market Growth Analysis up to 2024
Pompe disease is a rare, progressive, autosomal recessively inherited metabolic disorder, and is often a fatal muscular disease that affects one of the lysosomal enzymes. Pompe disease can also be called as a glycogen storage disease or acid alpha-glycosidase deficiency or GAA deficiency. It mainly occurs due to accumulation of glycogen in some tissues and organs, particularly muscles, leading to abnormal functioning. The inability of breaking the lysosomal glycogen lies
Pompe Disease Market Intelligence with Competitive Landscape 2024
Pompe disease is a rare, progressive, autosomal recessively inherited metabolic disorder, and is often a fatal muscular disease that affects one of the lysosomal enzymes. Pompe disease can also be called as a glycogen storage disease or acid alpha-glycosidase deficiency or GAA deficiency. It mainly occurs due to accumulation of glycogen in some tissues and organs, particularly muscles, leading to abnormal functioning. The inability of breaking the lysosomal glycogen lies
Pompe Disease Market Size – Industry Share Report 2024
Pompe disease is a rare, progressive, autosomal recessively inherited metabolic disorder, and is often a fatal muscular disease that affects one of the lysosomal enzymes. Pompe disease can also be called as a glycogen storage disease or acid alpha-glycosidase deficiency or GAA deficiency. It mainly occurs due to accumulation of glycogen in some tissues and organs, particularly muscles, leading to abnormal functioning. The inability of breaking the lysosomal glycogen lies